nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—SLC47A1—Metformin—polycystic ovary syndrome	0.587	1	CbGbCtD
Sirolimus—EIF4E—embryo—polycystic ovary syndrome	0.0084	0.0796	CbGeAlD
Sirolimus—EIF4E—uterus—polycystic ovary syndrome	0.00566	0.0536	CbGeAlD
Sirolimus—EIF4E—endocrine gland—polycystic ovary syndrome	0.00431	0.0408	CbGeAlD
Sirolimus—FGF2—endometrium—polycystic ovary syndrome	0.00375	0.0355	CbGeAlD
Sirolimus—FGF2—uterus—polycystic ovary syndrome	0.00345	0.0327	CbGeAlD
Sirolimus—FGF2—pituitary gland—polycystic ovary syndrome	0.00339	0.0321	CbGeAlD
Sirolimus—FGF2—adipose tissue—polycystic ovary syndrome	0.00338	0.032	CbGeAlD
Sirolimus—MTOR—embryo—polycystic ovary syndrome	0.00325	0.0308	CbGeAlD
Sirolimus—Azotaemia—Metformin—polycystic ovary syndrome	0.00315	0.052	CcSEcCtD
Sirolimus—Acidosis—Metformin—polycystic ovary syndrome	0.00303	0.0501	CcSEcCtD
Sirolimus—FGF2—adrenal gland—polycystic ovary syndrome	0.00303	0.0287	CbGeAlD
Sirolimus—CYP3A4—urine—polycystic ovary syndrome	0.00295	0.028	CbGeAlD
Sirolimus—FGF2—female gonad—polycystic ovary syndrome	0.00282	0.0268	CbGeAlD
Sirolimus—FGF2—vagina—polycystic ovary syndrome	0.00281	0.0266	CbGeAlD
Sirolimus—Nail disorder—Metformin—polycystic ovary syndrome	0.00259	0.0427	CcSEcCtD
Sirolimus—FKBP1A—adrenal cortex—polycystic ovary syndrome	0.00239	0.0227	CbGeAlD
Sirolimus—MTOR—endometrium—polycystic ovary syndrome	0.00238	0.0225	CbGeAlD
Sirolimus—MTOR—uterus—polycystic ovary syndrome	0.00219	0.0208	CbGeAlD
Sirolimus—MTOR—pituitary gland—polycystic ovary syndrome	0.00215	0.0204	CbGeAlD
Sirolimus—MTOR—adipose tissue—polycystic ovary syndrome	0.00214	0.0203	CbGeAlD
Sirolimus—FKBP1A—endometrium—polycystic ovary syndrome	0.00214	0.0203	CbGeAlD
Sirolimus—SLC47A1—adrenal cortex—polycystic ovary syndrome	0.00206	0.0195	CbGeAlD
Sirolimus—FKBP1A—uterus—polycystic ovary syndrome	0.00197	0.0187	CbGeAlD
Sirolimus—FKBP1A—pituitary gland—polycystic ovary syndrome	0.00193	0.0183	CbGeAlD
Sirolimus—FKBP1A—adipose tissue—polycystic ovary syndrome	0.00193	0.0183	CbGeAlD
Sirolimus—MTOR—adrenal gland—polycystic ovary syndrome	0.00192	0.0182	CbGeAlD
Sirolimus—Accidental injury—Metformin—polycystic ovary syndrome	0.0019	0.0313	CcSEcCtD
Sirolimus—CYP3A7—endocrine gland—polycystic ovary syndrome	0.00185	0.0176	CbGeAlD
Sirolimus—SLC47A1—endometrium—polycystic ovary syndrome	0.00184	0.0174	CbGeAlD
Sirolimus—MTOR—female gonad—polycystic ovary syndrome	0.00179	0.017	CbGeAlD
Sirolimus—MTOR—vagina—polycystic ovary syndrome	0.00178	0.0169	CbGeAlD
Sirolimus—FKBP1A—adrenal gland—polycystic ovary syndrome	0.00173	0.0164	CbGeAlD
Sirolimus—SLC47A1—uterus—polycystic ovary syndrome	0.00169	0.016	CbGeAlD
Sirolimus—MTOR—endocrine gland—polycystic ovary syndrome	0.00167	0.0158	CbGeAlD
Sirolimus—SLC47A1—pituitary gland—polycystic ovary syndrome	0.00166	0.0158	CbGeAlD
Sirolimus—SLC47A1—adipose tissue—polycystic ovary syndrome	0.00166	0.0157	CbGeAlD
Sirolimus—FKBP1A—female gonad—polycystic ovary syndrome	0.00161	0.0153	CbGeAlD
Sirolimus—FKBP1A—vagina—polycystic ovary syndrome	0.0016	0.0152	CbGeAlD
Sirolimus—Neuropathy—Metformin—polycystic ovary syndrome	0.00158	0.026	CcSEcCtD
Sirolimus—FKBP1A—endocrine gland—polycystic ovary syndrome	0.0015	0.0142	CbGeAlD
Sirolimus—SLC47A1—adrenal gland—polycystic ovary syndrome	0.00149	0.0141	CbGeAlD
Sirolimus—Ear pain—Metformin—polycystic ovary syndrome	0.00143	0.0236	CcSEcCtD
Sirolimus—SLC47A1—female gonad—polycystic ovary syndrome	0.00139	0.0131	CbGeAlD
Sirolimus—SLC47A1—vagina—polycystic ovary syndrome	0.00138	0.013	CbGeAlD
Sirolimus—Injury—Metformin—polycystic ovary syndrome	0.00133	0.0219	CcSEcCtD
Sirolimus—SLC47A1—endocrine gland—polycystic ovary syndrome	0.00129	0.0122	CbGeAlD
Sirolimus—Renal impairment—Metformin—polycystic ovary syndrome	0.00128	0.0211	CcSEcCtD
Sirolimus—SLCO1B1—endocrine gland—polycystic ovary syndrome	0.00127	0.012	CbGeAlD
Sirolimus—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00125	0.0206	CcSEcCtD
Sirolimus—Dehydration—Metformin—polycystic ovary syndrome	0.00113	0.0187	CcSEcCtD
Sirolimus—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00112	0.0186	CcSEcCtD
Sirolimus—Breast disorder—Metformin—polycystic ovary syndrome	0.0011	0.0182	CcSEcCtD
Sirolimus—Abdominal distension—Metformin—polycystic ovary syndrome	0.00106	0.0175	CcSEcCtD
Sirolimus—Influenza—Metformin—polycystic ovary syndrome	0.00105	0.0174	CcSEcCtD
Sirolimus—Pancreatitis—Metformin—polycystic ovary syndrome	0.00103	0.017	CcSEcCtD
Sirolimus—Neutropenia—Metformin—polycystic ovary syndrome	0.000985	0.0163	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000979	0.0162	CcSEcCtD
Sirolimus—Infestation NOS—Metformin—polycystic ovary syndrome	0.000939	0.0155	CcSEcCtD
Sirolimus—Infestation—Metformin—polycystic ovary syndrome	0.000939	0.0155	CcSEcCtD
Sirolimus—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00092	0.0152	CcSEcCtD
Sirolimus—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000888	0.0147	CcSEcCtD
Sirolimus—Rhinitis—Metformin—polycystic ovary syndrome	0.000845	0.014	CcSEcCtD
Sirolimus—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000839	0.00795	CbGeAlD
Sirolimus—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000839	0.0138	CcSEcCtD
Sirolimus—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00083	0.0137	CcSEcCtD
Sirolimus—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000828	0.0137	CcSEcCtD
Sirolimus—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000782	0.0129	CcSEcCtD
Sirolimus—Angiopathy—Metformin—polycystic ovary syndrome	0.000765	0.0126	CcSEcCtD
Sirolimus—Immune system disorder—Metformin—polycystic ovary syndrome	0.000761	0.0126	CcSEcCtD
Sirolimus—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00076	0.0125	CcSEcCtD
Sirolimus—Chills—Metformin—polycystic ovary syndrome	0.000756	0.0125	CcSEcCtD
Sirolimus—Malnutrition—Metformin—polycystic ovary syndrome	0.000734	0.0121	CcSEcCtD
Sirolimus—Flatulence—Metformin—polycystic ovary syndrome	0.000723	0.0119	CcSEcCtD
Sirolimus—Muscle spasms—Metformin—polycystic ovary syndrome	0.000706	0.0116	CcSEcCtD
Sirolimus—CYP3A5—female gonad—polycystic ovary syndrome	0.000702	0.00665	CbGeAlD
Sirolimus—CYP3A5—vagina—polycystic ovary syndrome	0.000697	0.00661	CbGeAlD
Sirolimus—Tremor—Metformin—polycystic ovary syndrome	0.000688	0.0114	CcSEcCtD
Sirolimus—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000681	0.0112	CcSEcCtD
Sirolimus—ABCB1—embryo—polycystic ovary syndrome	0.000676	0.0064	CbGeAlD
Sirolimus—Malaise—Metformin—polycystic ovary syndrome	0.000662	0.0109	CcSEcCtD
Sirolimus—Syncope—Metformin—polycystic ovary syndrome	0.000658	0.0109	CcSEcCtD
Sirolimus—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000653	0.00618	CbGeAlD
Sirolimus—Palpitations—Metformin—polycystic ovary syndrome	0.000648	0.0107	CcSEcCtD
Sirolimus—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000645	0.0106	CcSEcCtD
Sirolimus—Hypertension—Metformin—polycystic ovary syndrome	0.000634	0.0105	CcSEcCtD
Sirolimus—Myalgia—Metformin—polycystic ovary syndrome	0.000625	0.0103	CcSEcCtD
Sirolimus—Chest pain—Metformin—polycystic ovary syndrome	0.000625	0.0103	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00062	0.0102	CcSEcCtD
Sirolimus—Discomfort—Metformin—polycystic ovary syndrome	0.000617	0.0102	CcSEcCtD
Sirolimus—Oedema—Metformin—polycystic ovary syndrome	0.000599	0.00989	CcSEcCtD
Sirolimus—Infection—Metformin—polycystic ovary syndrome	0.000595	0.00982	CcSEcCtD
Sirolimus—Shock—Metformin—polycystic ovary syndrome	0.000589	0.00973	CcSEcCtD
Sirolimus—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000587	0.0097	CcSEcCtD
Sirolimus—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000586	0.00968	CcSEcCtD
Sirolimus—Skin disorder—Metformin—polycystic ovary syndrome	0.000582	0.0096	CcSEcCtD
Sirolimus—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000579	0.00956	CcSEcCtD
Sirolimus—Anorexia—Metformin—polycystic ovary syndrome	0.000571	0.00942	CcSEcCtD
Sirolimus—Hypotension—Metformin—polycystic ovary syndrome	0.00056	0.00924	CcSEcCtD
Sirolimus—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000554	0.00525	CbGeAlD
Sirolimus—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000546	0.00901	CcSEcCtD
Sirolimus—Paraesthesia—Metformin—polycystic ovary syndrome	0.000538	0.00888	CcSEcCtD
Sirolimus—Dyspnoea—Metformin—polycystic ovary syndrome	0.000534	0.00881	CcSEcCtD
Sirolimus—Somnolence—Metformin—polycystic ovary syndrome	0.000532	0.00879	CcSEcCtD
Sirolimus—Dyspepsia—Metformin—polycystic ovary syndrome	0.000527	0.0087	CcSEcCtD
Sirolimus—Decreased appetite—Metformin—polycystic ovary syndrome	0.000521	0.00859	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000517	0.00854	CcSEcCtD
Sirolimus—Constipation—Metformin—polycystic ovary syndrome	0.000512	0.00845	CcSEcCtD
Sirolimus—ABCB1—endometrium—polycystic ovary syndrome	0.000495	0.00469	CbGeAlD
Sirolimus—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000494	0.00815	CcSEcCtD
Sirolimus—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00049	0.00464	CbGeAlD
Sirolimus—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00049	0.00808	CcSEcCtD
Sirolimus—Abdominal pain—Metformin—polycystic ovary syndrome	0.000473	0.00782	CcSEcCtD
Sirolimus—ABCB1—uterus—polycystic ovary syndrome	0.000456	0.00432	CbGeAlD
Sirolimus—ABCB1—pituitary gland—polycystic ovary syndrome	0.000448	0.00424	CbGeAlD
Sirolimus—ABCB1—adipose tissue—polycystic ovary syndrome	0.000446	0.00422	CbGeAlD
Sirolimus—Asthenia—Metformin—polycystic ovary syndrome	0.00043	0.00709	CcSEcCtD
Sirolimus—Pruritus—Metformin—polycystic ovary syndrome	0.000424	0.007	CcSEcCtD
Sirolimus—Diarrhoea—Metformin—polycystic ovary syndrome	0.00041	0.00676	CcSEcCtD
Sirolimus—ABCB1—adrenal gland—polycystic ovary syndrome	0.0004	0.00379	CbGeAlD
Sirolimus—Dizziness—Metformin—polycystic ovary syndrome	0.000396	0.00654	CcSEcCtD
Sirolimus—Vomiting—Metformin—polycystic ovary syndrome	0.000381	0.00629	CcSEcCtD
Sirolimus—Rash—Metformin—polycystic ovary syndrome	0.000378	0.00623	CcSEcCtD
Sirolimus—Dermatitis—Metformin—polycystic ovary syndrome	0.000377	0.00623	CcSEcCtD
Sirolimus—Headache—Metformin—polycystic ovary syndrome	0.000375	0.00619	CcSEcCtD
Sirolimus—ABCB1—female gonad—polycystic ovary syndrome	0.000373	0.00353	CbGeAlD
Sirolimus—ABCB1—vagina—polycystic ovary syndrome	0.000371	0.00351	CbGeAlD
Sirolimus—Nausea—Metformin—polycystic ovary syndrome	0.000356	0.00587	CcSEcCtD
Sirolimus—ABCB1—endocrine gland—polycystic ovary syndrome	0.000347	0.00329	CbGeAlD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	2.49e-05	0.000101	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—IRS1—polycystic ovary syndrome	2.48e-05	0.0001	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—GNAS—polycystic ovary syndrome	2.47e-05	0.0001	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IRS1—polycystic ovary syndrome	2.47e-05	9.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TAB1—polycystic ovary syndrome	2.47e-05	9.99e-05	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—polycystic ovary syndrome	2.46e-05	9.97e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SULT2A1—polycystic ovary syndrome	2.46e-05	9.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.45e-05	9.93e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKR1C1—polycystic ovary syndrome	2.45e-05	9.93e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PRL—polycystic ovary syndrome	2.44e-05	9.9e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PLAT—polycystic ovary syndrome	2.44e-05	9.88e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GHRL—polycystic ovary syndrome	2.44e-05	9.88e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—STAR—polycystic ovary syndrome	2.41e-05	9.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGF18—polycystic ovary syndrome	2.41e-05	9.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—TCF7L2—polycystic ovary syndrome	2.41e-05	9.74e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TEAD2—polycystic ovary syndrome	2.4e-05	9.73e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKR1C2—polycystic ovary syndrome	2.4e-05	9.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RBP4—polycystic ovary syndrome	2.39e-05	9.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT2—polycystic ovary syndrome	2.39e-05	9.68e-05	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—VEGFA—polycystic ovary syndrome	2.38e-05	9.65e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—RRM2—polycystic ovary syndrome	2.38e-05	9.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SLC2A4—polycystic ovary syndrome	2.37e-05	9.58e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—INS—polycystic ovary syndrome	2.36e-05	9.57e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IRS1—polycystic ovary syndrome	2.36e-05	9.54e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.36e-05	9.54e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	2.33e-05	9.43e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ATF1—polycystic ovary syndrome	2.33e-05	9.43e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IRS2—polycystic ovary syndrome	2.32e-05	9.4e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CRP—polycystic ovary syndrome	2.32e-05	9.4e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRG1—polycystic ovary syndrome	2.31e-05	9.36e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	2.3e-05	9.3e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—YAP1—polycystic ovary syndrome	2.3e-05	9.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT2—polycystic ovary syndrome	2.29e-05	9.29e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT2—polycystic ovary syndrome	2.29e-05	9.25e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.27e-05	9.19e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—POMC—polycystic ovary syndrome	2.27e-05	9.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PRL—polycystic ovary syndrome	2.26e-05	9.14e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—INS—polycystic ovary syndrome	2.26e-05	9.14e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SULT2A1—polycystic ovary syndrome	2.26e-05	9.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MTHFR—polycystic ovary syndrome	2.25e-05	9.12e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—YAP1—polycystic ovary syndrome	2.23e-05	9.03e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NAMPT—polycystic ovary syndrome	2.21e-05	8.93e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GAB1—polycystic ovary syndrome	2.2e-05	8.91e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.19e-05	8.88e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—RRM2—polycystic ovary syndrome	2.19e-05	8.85e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IGF1—polycystic ovary syndrome	2.18e-05	8.84e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT2—polycystic ovary syndrome	2.18e-05	8.83e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP11A1—polycystic ovary syndrome	2.18e-05	8.82e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	2.18e-05	8.81e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SERPINE1—polycystic ovary syndrome	2.17e-05	8.79e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.16e-05	8.75e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HMMR—polycystic ovary syndrome	2.15e-05	8.71e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NGFR—polycystic ovary syndrome	2.15e-05	8.7e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IRS2—polycystic ovary syndrome	2.14e-05	8.68e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	2.14e-05	8.67e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PRL—polycystic ovary syndrome	2.13e-05	8.62e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—YAP1—polycystic ovary syndrome	2.11e-05	8.53e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—INSR—polycystic ovary syndrome	2.1e-05	8.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—BCL2—polycystic ovary syndrome	2.09e-05	8.45e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.07e-05	8.39e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL18—polycystic ovary syndrome	2.06e-05	8.33e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKR1C3—polycystic ovary syndrome	2.06e-05	8.33e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HSD3B1—polycystic ovary syndrome	2.05e-05	8.31e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	2.05e-05	8.29e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IRS1—polycystic ovary syndrome	2.03e-05	8.2e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP17A1—polycystic ovary syndrome	2.02e-05	8.2e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NAMPT—polycystic ovary syndrome	2.02e-05	8.19e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.02e-05	8.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL6—polycystic ovary syndrome	2.02e-05	8.18e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PNPLA2—polycystic ovary syndrome	2.01e-05	8.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRG1—polycystic ovary syndrome	2.01e-05	8.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2e-05	8.1e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP11A1—polycystic ovary syndrome	2e-05	8.09e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	1.99e-05	8.06e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.98e-05	8.02e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.97e-05	7.97e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PGR—polycystic ovary syndrome	1.95e-05	7.89e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—LEP—polycystic ovary syndrome	1.94e-05	7.85e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SRD5A1—polycystic ovary syndrome	1.91e-05	7.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—IL6—polycystic ovary syndrome	1.89e-05	7.67e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NCOR1—polycystic ovary syndrome	1.89e-05	7.66e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKR1C3—polycystic ovary syndrome	1.89e-05	7.64e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT2—polycystic ovary syndrome	1.88e-05	7.59e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	1.87e-05	7.59e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	1.87e-05	7.59e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GNAS—polycystic ovary syndrome	1.87e-05	7.59e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—LHB—polycystic ovary syndrome	1.87e-05	7.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IRS1—polycystic ovary syndrome	1.87e-05	7.57e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP17A1—polycystic ovary syndrome	1.86e-05	7.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRG1—polycystic ovary syndrome	1.86e-05	7.52e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HSD3B2—polycystic ovary syndrome	1.83e-05	7.41e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—STAR—polycystic ovary syndrome	1.82e-05	7.38e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	1.82e-05	7.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PLAT—polycystic ovary syndrome	1.81e-05	7.33e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GHRL—polycystic ovary syndrome	1.81e-05	7.33e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—INS—polycystic ovary syndrome	1.79e-05	7.25e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.79e-05	7.23e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKR1C1—polycystic ovary syndrome	1.77e-05	7.18e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.75e-05	7.09e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TH—polycystic ovary syndrome	1.75e-05	7.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	1.74e-05	7.05e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	1.74e-05	7.03e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT2—polycystic ovary syndrome	1.73e-05	7.01e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.73e-05	7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ATF1—polycystic ovary syndrome	1.73e-05	7e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CRP—polycystic ovary syndrome	1.72e-05	6.97e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IRS2—polycystic ovary syndrome	1.72e-05	6.97e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SLC2A4—polycystic ovary syndrome	1.7e-05	6.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.69e-05	6.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MTHFR—polycystic ovary syndrome	1.67e-05	6.77e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—POMC—polycystic ovary syndrome	1.66e-05	6.74e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—INS—polycystic ovary syndrome	1.66e-05	6.7e-05	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—IL6—polycystic ovary syndrome	1.65e-05	6.67e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—SERPINE1—polycystic ovary syndrome	1.65e-05	6.66e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—BCL2—polycystic ovary syndrome	1.64e-05	6.63e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SULT2A1—polycystic ovary syndrome	1.63e-05	6.6e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	1.63e-05	6.59e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	1.62e-05	6.57e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TH—polycystic ovary syndrome	1.61e-05	6.51e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP19A1—polycystic ovary syndrome	1.6e-05	6.49e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF1—polycystic ovary syndrome	1.6e-05	6.48e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT2—polycystic ovary syndrome	1.6e-05	6.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NGFR—polycystic ovary syndrome	1.6e-05	6.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IRS2—polycystic ovary syndrome	1.59e-05	6.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PRL—polycystic ovary syndrome	1.58e-05	6.4e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—RRM2—polycystic ovary syndrome	1.58e-05	6.4e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SLC2A4—polycystic ovary syndrome	1.56e-05	6.33e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	1.55e-05	6.27e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	1.53e-05	6.19e-05	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL6—polycystic ovary syndrome	1.53e-05	6.18e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—YAP1—polycystic ovary syndrome	1.52e-05	6.16e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.52e-05	6.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IRS1—polycystic ovary syndrome	1.5e-05	6.09e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.5e-05	6.08e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.5e-05	6.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	1.48e-05	6e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	1.48e-05	6e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP19A1—polycystic ovary syndrome	1.47e-05	5.95e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—LEP—polycystic ovary syndrome	1.47e-05	5.95e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NAMPT—polycystic ovary syndrome	1.46e-05	5.92e-05	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IL6—polycystic ovary syndrome	1.46e-05	5.89e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP11A1—polycystic ovary syndrome	1.44e-05	5.85e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GNAS—polycystic ovary syndrome	1.43e-05	5.79e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.43e-05	5.77e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—LHB—polycystic ovary syndrome	1.41e-05	5.72e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT2—polycystic ovary syndrome	1.39e-05	5.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GNAS—polycystic ovary syndrome	1.39e-05	5.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IRS1—polycystic ovary syndrome	1.39e-05	5.62e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	1.38e-05	5.59e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKR1C3—polycystic ovary syndrome	1.36e-05	5.52e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NCOR1—polycystic ovary syndrome	1.36e-05	5.52e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP17A1—polycystic ovary syndrome	1.34e-05	5.44e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	1.34e-05	5.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—INS—polycystic ovary syndrome	1.33e-05	5.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.32e-05	5.36e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GNAS—polycystic ovary syndrome	1.31e-05	5.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.31e-05	5.3e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRG1—polycystic ovary syndrome	1.3e-05	5.26e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP1A1—polycystic ovary syndrome	1.29e-05	5.23e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT2—polycystic ovary syndrome	1.29e-05	5.2e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—POMC—polycystic ovary syndrome	1.26e-05	5.11e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—INS—polycystic ovary syndrome	1.25e-05	5.08e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NCOR1—polycystic ovary syndrome	1.25e-05	5.06e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	1.24e-05	5.03e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	1.23e-05	4.98e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SERPINE1—polycystic ovary syndrome	1.22e-05	4.94e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—BCL2—polycystic ovary syndrome	1.22e-05	4.92e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.21e-05	4.91e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.21e-05	4.91e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MTHFR—polycystic ovary syndrome	1.2e-05	4.87e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	1.19e-05	4.83e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP1A1—polycystic ovary syndrome	1.19e-05	4.8e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	1.18e-05	4.76e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TH—polycystic ovary syndrome	1.16e-05	4.71e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.15e-05	4.67e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	1.15e-05	4.65e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	1.13e-05	4.58e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	1.12e-05	4.54e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IRS2—polycystic ovary syndrome	1.11e-05	4.51e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MTHFR—polycystic ovary syndrome	1.11e-05	4.47e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	1.1e-05	4.47e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	1.09e-05	4.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—LEP—polycystic ovary syndrome	1.09e-05	4.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—polycystic ovary syndrome	1.08e-05	4.37e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	1.06e-05	4.3e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.05e-05	4.23e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—polycystic ovary syndrome	1.03e-05	4.18e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	1.03e-05	4.17e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	1.01e-05	4.1e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	1e-05	4.05e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—polycystic ovary syndrome	9.86e-06	3.99e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARG—polycystic ovary syndrome	9.76e-06	3.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IRS1—polycystic ovary syndrome	9.72e-06	3.94e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—POMC—polycystic ovary syndrome	9.63e-06	3.9e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—INS—polycystic ovary syndrome	9.58e-06	3.88e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	9.55e-06	3.86e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	9.49e-06	3.84e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—POMC—polycystic ovary syndrome	9.36e-06	3.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—INS—polycystic ovary syndrome	9.31e-06	3.77e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	9.04e-06	3.66e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1—polycystic ovary syndrome	9.01e-06	3.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT2—polycystic ovary syndrome	9e-06	3.64e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARG—polycystic ovary syndrome	8.96e-06	3.63e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—POMC—polycystic ovary syndrome	8.84e-06	3.58e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—INS—polycystic ovary syndrome	8.79e-06	3.56e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TH—polycystic ovary syndrome	8.77e-06	3.55e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	8.7e-06	3.52e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	8.57e-06	3.47e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.55e-06	3.46e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	8.53e-06	3.45e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	8.51e-06	3.44e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—polycystic ovary syndrome	8.48e-06	3.43e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	8.24e-06	3.34e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	8.02e-06	3.25e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	7.99e-06	3.23e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.93e-06	3.21e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—polycystic ovary syndrome	7.83e-06	3.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	7.58e-06	3.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	7.34e-06	2.97e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—polycystic ovary syndrome	7.23e-06	2.93e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	7.16e-06	2.9e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	7.08e-06	2.87e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	6.82e-06	2.76e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	6.8e-06	2.75e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	6.72e-06	2.72e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	6.48e-06	2.62e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	6.47e-06	2.62e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	6.39e-06	2.59e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—INS—polycystic ovary syndrome	6.35e-06	2.57e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	6.34e-06	2.57e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—polycystic ovary syndrome	6.29e-06	2.55e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	6.24e-06	2.53e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	6.03e-06	2.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.88e-06	2.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—polycystic ovary syndrome	5.81e-06	2.35e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—polycystic ovary syndrome	5.48e-06	2.22e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TH—polycystic ovary syndrome	5.4e-06	2.19e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	5.26e-06	2.13e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	4.94e-06	2e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	4.89e-06	1.98e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—POMC—polycystic ovary syndrome	4.82e-06	1.95e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—INS—polycystic ovary syndrome	4.79e-06	1.94e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	4.41e-06	1.79e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	4.2e-06	1.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—polycystic ovary syndrome	4.07e-06	1.65e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	3.98e-06	1.61e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	3.71e-06	1.5e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	3.01e-06	1.22e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	2.97e-06	1.2e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—INS—polycystic ovary syndrome	2.95e-06	1.2e-05	CbGpPWpGaD
